baber/WOPTO huggingface dataset:
Patent NZ-316441-A (NZ)
Title: Production and use of type 5 17beta-hydroxysteriod dehydrogenase
Inventor: LABRIE FERNAND
IPC: C12N15/12
Filed: 1996-09-12
Abstract: A 5 17'beta'-hydroxysteroid dehydrogenase is provided. Methods of producing the enzyme and using the enzyme to identify potential compounds that inhibit or alter the activity of the enzyme are described. In addition, methods of using the gene sequence or portions thereof for probes or to produce expression-disrupting sense or antisense DNA fragments thereof, or antisense RNA, are provided.
Patent NZ-325973-A (NZ)
Title: Medical use of an ACE-inhibitor (angiotensin converting enzyme) for treatment of peptic ulcer
Inventor: FANDRIKS LARS
IPC: A61K31/407
Filed: 1996-12-20
Abstract: The use of an ACE-inhibitor or a physiologically acceptable salt thereof for the manufacture of a medicament for the prophylaxis and/or treatment of dyspeptic symptoms of unknown origin.
Patent NZ-334168-A (NZ)
Title: Combination therapy for treatment of psychoses comprising administering an atypical antipsychotic such as olanzapine, in combination with an effective amount of a serotonin reuptake inhibitor
Inventor: BYMASTER FRANKLIN P
IPC: A61K31/445
Filed: 1997-09-09
Abstract: The specification describes a method for treating a patient suffering from or susceptible to psychosis, acute mania, mild anxiety states, or depression in combination with psychotic episodes.  The method involves administering an atypical antipsychotic, in combination with a serotonin reuptake inhibitor. The preferred combinations are as follows: olanzapine/fluoxetine olanzapine/venlafaxine olanzapine/citralopram olanzapine/fluvoxamine olanzapine/paroxetine olanzapine/sertraline olanzapine/milnacipran olanzapine/duloxetine clozapine/fluoxetine risperidone/fluoxetine sertindole/fluoxetine quetiapine/fluoxetine ziprasidone/fluoxetine The most preferred combination is to: Olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, is a known compound and is described in U.S. Patent No. 5,229,382 as being useful for the treatment of schizophrenia, schizophreniform disorder, acute mania, mild anxiety states, and psychosis. U.S. Patent No. 5,229,382 is herein incorporated by reference in its entirety and Fluoxetine, N-methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine, is marketed in the hydrochloride salt form, and as the racemic mixture of its two enantiomers. U.S. Patent 4,314,081 is an early reference on the compound. Robertson et al., J. Med. Chem. 31, 1412 (1988), taught the separation of the R and S enantiomers of fluoxetine and showed that their activity as serotonin uptake inhibitors is similar to each other. In this document, the word "fluoxetine" will be used to mean any acid addition salt or the free base, and to include either the racemic mixture or either of the R and S enantiomers;
Patent NZ-337809-A (NZ)
Title: Interconnection of video game machine, digital camera and portable computer
Inventor: CHATANI MASAYUKI
IPC: A63F13/26
Filed: 1999-09-14
Abstract: Master unit 2 is for executing program data recorded in a removably loaded recording medium and for processing data.  Imaging device 4 and slave unit 3 (having a display) are removably connected to unit 2.  Unit 2 processes image data communicated between device 4 and unit 3.
Patent NZ-501591-A (NZ)
Title: Secured sanitary catheter for administering liquids into cardiovascular system of animals during slaughter
Inventor: BERNHARDT DOUGLAS H
IPC: A23B4/02
Filed: 1998-06-05
Abstract: A secured sanitary catheter (2) for administration of treatment solution into animals comprises a catheter body (6) with a longitudinal bore (18) and a sanitary vascular securing device (16) attached to the catheter body. The catheter body has a proximal end and a distal end, with the longitudinal bore (18) terminating in an opening (20) at the distal end of the catheter body, for delivery of treatment solution into a vessel of an animal. The sanitary vascular securing device (16) contains a plurality of slots (62, 64, 66, 68, 70, 72) for mechanically and frictionally engaging the vessel at two or more points. The present invention further relates to a method for using the secured sanitary catheter of the present invention.
Patent NZ-501845-A (NZ)
Title: Transmission and attachment of signature tokens for hybrid mailing
Inventor: HARRIS CHRISTOPHER JOHN
Filed: 1999-12-16
Abstract: An electronic mail item is created at the user's computer and sent via the Internet to a processing center where it is replicated into its physical form to be delivered to the intended recipient.  Security is ensured by the creation of one or more user codes, specific to the user, which are stored at the processing center and the user's computer.  The codes include images such as signatures that can appear on the physical form.
Patent NZ-502248-A (NZ)
Title: Rechargeable containers and dispensers
Inventor: KLIMA WILLIAM L
IPC: B65D1/02
Filed: 1998-07-20
Abstract: Rechargeable containers and dispensers, in particular spray bottle dispensers including at least one chemical reservoir (816) for recharging the spray bottle dispenser (808). Preferably, a plurality of separate chemical reservoirs containing chemical concentrate are provided within the spray bottle dispenser (808) to fully contain any inadvertent spillage of chemicals, and to insure a high degree of safety against accidental spills, and/or accidental ingestion by children.
Patent NZ-509579-A (NZ)
Title: Peptide antagonists of zonulin and methods for use of the same
Inventor: FASANO ALESSIO
IPC: A61K38/08
Filed: 1999-07-28
Abstract: A peptide antagonist of zonulin can be selected from the amino acid sequences of SEQ ID NO:1-14, 16-22, 24 or 35, or can be selected from SEQ ID NO:15 or 23 wherein the peptide binds to a zonula occludens toxin receptor yet does not physiologically modulate the opening of mammalian tight junctions. The amino acid sequences of SEQ ID NO:1-24 wherein the antagonists bind to a zonula occludens toxin receptor in the intestine yet does not physiologically modulate the opening of mammalian tight junctions of the intestine are useful for the treatment of a gastrointestinal inflammation. The peptide with amino acid sequence SEQ ID NO:35 is useful in treating a condition associated with breakdown of the blood brain barrier.
Patent NZ-511341-A (NZ)
Title: Dual isolation valve with rectangular flow passageways
Inventor: RAINWATER EDWARD L
IPC: F16K27/06
Filed: 1999-08-31
Abstract: A dual isolation valve10, comprising; (i) a valve body12, which defines an inner cavity, with opposed inlet 14 and outlet 40 ports, which define a flow axis that extends therebetween; (ii) a first valve member that has a narrower first end and a wider second end is rotatably mounted within the inner cavity about a first axis of rotation perpendicular to the flow axis, The first end of the first valve member extends away from the second end along the first axis of rotation in a first direction.  The first valve member has a rectangular flow passage, and is rotatable between an open position, in which the flow passage is oriented to be generally aligned with and located on the flow axis to enable fluid entering the inlet port to pass through the flow passage, and a closed position, in which the flow passage is oriented to be perpendicular to the flow axis to prevent fluid entering the inlet port from passing through the flow passage. (iii) a second valve member that has a narrower first end and a wider second end and is rotatably mounted within the inner cavity about a second axis of rotation perpendicular to the flow axis. The first end extends away from the second end along the second axis of rotation in a second direction opposite to the first direction.  The second valve member has a rectangular flow passage and is rotatable between an open position, in which the flow passage is oriented to be aligned with and located on the flow axis to enable fluid exiting the first valve member to pass through the flow passage to the outlet port, and a closed position, in which the flow passage is oriented to be perpendicular to the flow axis to prevent fluid exiting the first valve member from passing through the flow passage to the outlet port.
Patent NZ-512835-A (NZ)
Title: Genes identified as required for proliferation in escherichia coli
Inventor: FORSYTH R ALLYN
IPC: A61K48/00
Filed: 2000-01-27
Abstract: A purified or isolated nucleic acid consists essentially of the nucleotide sequence of SEQ ID NO:405 wherein the nucleic acid inhibits microorganism proliferation, and can encode a polypeptide comprising the amino acid sequence of SEQ ID NO:243. Vectors, host cells, antibodies and methods of producing the polypeptide are described are described. Also described are methods of identifying compounds that inhibit the activity or reduce the amount of the polypeptide or its gene product and for identifying bacterial strains and genes in a microorganism required for proliferation. The nucleic acid comprising SEQ ID NO:82 or 405 can be used in the manufacture of a medicament for inhibiting cellular proliferation of a population of cells
Patent NZ-513961-A (NZ)
Title: Eplerenone crystalline form exhibiting enhanced dissolution rate
Inventor: BARTON KATHLEEN
IPC: A61P9/04
Filed: 2000-12-04
Abstract: Disclosed are crystalline forms of eplerenone, including Form H, which has an orthorhombic crystal system and an X-ray powder diffraction pattern comprising a peak at 12.0± 0.2 degrees 2è. The crystalline forms are used in the manufacture of medicaments for treating disorders mediated by aldosterone.
Patent NZ-516771-A (NZ)
Title: Antitumor antibodies, proteins, and uses thereof
Inventor: ROCK KENNETH L
IPC: G01N33/574
Filed: 2000-07-18
Abstract: An isolated monoclonal antibody or antigen binding fragment binds to fetal thymocytes, inhibits proliferation of and induces apoptosis in a cell upon bind the cell and either does not bind adult thymocytes, does not bind to adult bone marrow and/or does not bind to adult B and/or T cells. Preferably the antibody is produced by the hybridoma cell line ATCC No. PTA-377, PTA-404 or PTA-405. Also described is a pharmaceutical composition comprising the antibody and the use of the antibody in the manufacture of a medicament for detecting a tumor cell, inducing apoptosis and inhibiting tumor cell proliferation. Also described are in vitro methods for diagnosing tumor and isolating a protein.
Patent NZ-517122-A (NZ)
Title: Novel B7-4 molecules and uses therefor
Inventor: FREEMAN GORDON
IPC: C07K14/705
Filed: 2000-08-23
Abstract: The invention provides isolated nucleic acids molecules, designated B7-4 nucleic acid molecules, which encode novel B7-4 polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing B7-4 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a B7-4 gene has been introduced or disrupted. The invention still further provides isolated B7-4 proteins, fusion proteins, antigenic peptides and anti-B7-4 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
Patent NZ-517458-A (NZ)
Title: Pesticide formulations containing phosphate ester surfactant and alkoxylated lignosulfonate
Inventor: CHOW VICTOR SHUI-CHIU
IPC: C09K23/50
Filed: 2000-09-18
Abstract: A surfactant system comprising: a) at least one ethoxylated polyarylphenol phosphate ester of the formula (1), where R3 and R6 are independently selected from the group consisting of hydrogen, sodium, potassium and formula (2) - where n is a number from 4 to 25 inclusive, and b) at least one ethoxylated lignosulfonate salt having an average number of ethylene oxide units (EO) equal to 1 to 4.
Patent NZ-519348-A (NZ)
Title: Fragments and antagonists of heat shock protein 60
Inventor: KOLB HUBERT
IPC: A01N63/00
Filed: 2000-12-14
Abstract: Disclosed is a peptide, or a variant, derivative or analog of a fragment of hsp60 having the ability to act as an antagonist of hsp60 characterised by its ability to reduce or prevent the induction of a pro-inflammatory immune response of cells of the innate immune system by hsp60 by inhibiting the binding of hsp60 to a Toll like receptor, wherein the fragment consists of five to thirty amino acids selected from a group as defined. The disclosed peptide is useful in treating inflammatory disease, especially those selected from the group: autoimmune disease, diabetes, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, systemic lupus erythematosis, chronic inflammation, artherosclerosis, inflammatory bowel disease, reactive arthritis, chronic infections, graft rejection, gingivitis, gastritis, ulcer, thrombosis, allergy and acute infections.
Patent NZ-520719-A (NZ)
Title: Novel compounds
Inventor: HANSEN PETER
IPC: C07D209/08
Filed: 2001-02-23
Abstract: A compound of formula (I") where; m is 0, 1, 2 or 3 ; each Rl independently represents halogen, cyano, nitro, carboxyl, hydroxyl, C3-C6 cycloalkyl, C1-C6 alkoxy, C1-C6 alkoxycarbonyl, C1-C6 haloalkyl, C1-C6 haloalkoxy, -NR9R10, C3-C6 cycloalkylamino, C1-C6 alkylthio, C1-C6 alkylcarbonyl, C1-C6 alkylcarbonylamino, sulphonamido, C1-C6 alkylsulphonyl, -C (O) NR11R12, -NR13 C(O)-(NH)pR14, phenyl, or C1-C6 alkyl optionally substituted by carboxyl or C1-C6 alkoxycarbonyl ; p is 0 or 1; X represents an oxygen or sulphur atom or a CH2, CH (CH3),OCH2, CH2O,CH2NH, NH or carbonyl group and Y represents a nitrogen atom or a CH or C (OH) group, provided that when X represents an oxygen or sulphur atom or a CH2O, CH2NH or NH group, then Y represents a CH group; Z1 represents a bond or a group (CH2)q where q is 1 or 2; Z2 represents a bond or a group CH2, with the proviso that Z1 and Z2 do not both simultaneously represent a bond; Q represents an oxygen or sulphur atom or a group CH2 or NH; R2 represents a group n is 0, 1 or 2 ; each R3 independently represents a C1-C6 alkyl, C1-C6 alkoxycarbonyl, -CH2OH or carboxyl group; R4,R5, R6 and R each independently represent a hydrogen atom or a C1-C6 alkyl group, or R4,R5, R6 and R7 together represent a C1-C4 alkylene chain linking the two carbon atoms to which they are attached to form a 4-to 7-membered saturated carbocycle, or R5, R6 and R each represent a hydrogen atom and R4 and R8 together with the carbon atoms to which they are attached form a 5- to 6-membered saturated carbocycle; R8 represents a hydrogen atom, a C1-C6 alkyl group or is linked to R4 as defined above; R9 and R10 each independently represent a hydrogen atom or a C1-C6 alkyl group, or R9 and R10 together with the nitrogen atom to which they are attached form a 4- to 7membered saturated heterocycle; R11 and R12 each independently represent a hydrogen atom or a C1-C6 alkyl group optionally substituted by C1-C6 alkoxycarbonyl ; R represents a hydrogen atom or a C1-C6 alkyl group ; and R14 represents a hydrogen atom, or a C1-C6 alkyl group optionally substituted by carboxyl, C1-C6 alkoxy or 1-C6 alkoxycarbonyl; provided that when X is an oxygen atom or a group CH2, Y is CH, Z1 and Z2 each represent a group CH2 and Q is an oxygen atom, then R2 is other than an unsubstituted indolyl group; Use of a compound of formula (I") in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of chemokine receptor activity is beneficial for example, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, multiple sclerosis.
Patent NZ-522407-A (NZ)
Title: Process for the preparation of dihydroxy esters and derivatives thereof
Inventor: HOLT ROBERT ANTONY
IPC: C12P7/62
Filed: 2001-05-01
Abstract: A process is provided for the preparation of a compound of Formula 1 wherein R and R' represent optionally substituted hydrocarbyl groups and X represents a hydrocarbyl linking group. The process comprises either the stereoselective reduction of the keto group in a dihydroxy keto precursor followed by selective esterification of a primary hydroxy, or selective esterification of a primary hydroxy of a dihydroxy keto precursor followed by stereoselective reduction of the keto group.
Patent NZ-522671-A (NZ)
Title: A transportation and installation assist device for at least one pre-cast concrete tilt panel
Inventor: BURKE JOHN THOMAS
IPC: B60P3/022
Filed: 2001-05-28
Abstract: Described is a transportation and installation assist device 16 for at least one pre-cast concrete tilt panel 18. The panels are generally rectangular and have at least one lifting anchor at one of the shorter ends 44. The device 16 includes at least one frame 20 adapted to releasably engage one of the panels at the second end 48 and support the panel in a loading/transport orientation with the face of the associated panel substantially vertical and said axis 50 substantially horizontal. The frame is also adapted for pivotal mounting to a table bed 14 of a truck 10 or trailer 12. The frame and associated panel pivot together when the first panel end 44 is lifted above the second panel end 48 until the panel is in a releasing orientation with the face of the panel substantially vertical and said axis substantially vertical. Further lifting of the first panel end 44 releases the panel from the frame 20.
Patent NZ-524049-A (NZ)
Title: Process for the preparation of 4-thioalkylbromobenzene derivatives
Inventor: LOCHTMAN RENE
IPC: C07D261/04
Filed: 2001-07-17
Abstract: A process for preparing 4-thioalkylbromobenzene derivatives such as 4-methylthio-3-(4,5-dihydroisoxazol-3-yl)-2-methylbromobenzene of the formula (I) is disclosed, wherein: R1 is C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C3-C8-cycloalkyl or a halogen; R2 is C1-C6-alkyl, C1-C6-alkoxy, C3-C8-cycloalkyl, C2-C6-alkenyl, cyano or a heterocyclic radical; R3 is C1-C6-alkyl; which comprises reacting a compound of the formula (II), in which R1 and R2 are as defined above, with a dialkyl disulfide of the formula (III) in the presence of a nitrite such as sodium nitrite and a catalyst such as copper powder in a suitable solvent. The reaction may be carried out at temperatures between 30-100 degree C
Patent NZ-526076-A (NZ)
Title: Composition for regulating animal growth, method of manufacture and the use thereof
Inventor: CHI FRANCIS
IPC: A23K1/00
Filed: 2001-12-12
Abstract: The use of a composition for regulating growth in non-human animals, wherein said composition comprises 1 to 95wt% of cysteamine or its salt, and an inclusion compound host material composition comprising a stabilizer selected from a group including cyclodextrin or its derivative, is disclosed. Also described is a veterinary composition when used for regulating growth in non-human animals comprising 1 to 95wt% of cysteamine or its salt, an inclusion compound host material composition comprising a stabilizer selected from a group including veterinarily acceptable cyclodextrin or a derivative thereof and a veterinarily acceptable carrier. A method of preparing this composition is disclosed. Animal feed additives and animal feeds comprising the above composition are also described.
Patent NZ-526097-A (NZ)
Title: Online diagnosing of computer hardware and software from a remote location without requiring human assistance
Inventor: WING ROBERT
IPC: G06F11/30
Filed: 2001-11-15
Abstract: A method for remotely diagnosing a computer, comprise: establishing communication between a server (104) and a communications interface (404) associated with a client computer (108); establishing communication between a client application (400) operating on the client computer (108) and the server (104); in response to a signal associated with the communications interface (404) and received by the server (104), downloading a first diagnostic tool from the server (104) to the client application (400); executing the first diagnostic tool; returning a result from the client application (400) to the server (104); and returning a disposition from the server (104) to the communications interface (404).
Patent NZ-527173-A (NZ)
Title: Specific human antibodies for selective cancer therapy
Inventor: HAGAI YOCHEVED
IPC: C07K16/18
Filed: 2001-12-31
Abstract: A peptide fragment that comprises an Fv molecule, wherein said Fv molecule comprises a heavy chain variable region and a light chain variable region, and wherein the Fv is a scFV or a dsFv capable of binding one or more cell types selected from the group consisting of leukemia cells and cells expressing glycocalicin.
Patent NZ-528706-A (NZ)
Title: Removable, essentially cylindrical implants
Inventor: FREITAG LUTZ
IPC: A61F2/95
Filed: 2002-04-05
Abstract: The invention relates to removable, essentially cylindrical implants that are characterized in that they can be reduced in diameter and that one or more elastic, thin wire structures (2a, 2b) that has/have a catch element (3a, 3b) at least on one end thereof are singly or multiply wound around them at one or more levels.
Patent NZ-531261-A (NZ)
Title: Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3- trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity
Inventor: BUTLIN ROGER JOHN
IPC: A61K31/495
Filed: 2002-08-21
Abstract: Disclosed are compounds of the formula (I) wherein: R is methyl or mesyl; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof. Further disclosed are a process for the production of the compounds of formula (I), and the use of those compounds in the preparation of medicaments for use in elevation of PDH activity, and the treatment of diabetes mellitus.
Patent NZ-531389-A (NZ)
Title: Botulinum toxin in the treatment or prevention of acne vulgaris
Inventor: SUSKIND DANA L
IPC: A61K38/00
Filed: 2002-07-25
Abstract: Botulinum toxin can be used in the preparation of a medicament for the treatment or prevention of acne vulgaris. The botulinum toxin may be botulinum toxin A, B, C, D, E, F or G. The medicament can also be suitable for the treatment of both acne vulgaris and rhytids in a human who is susceptible to both acne vulgaris and rhytids.
Patent NZ-533838-A (NZ)
Title: Mounting apparatus for sliding door assembly
Inventor: KENNY PHILIP RICHARD
Filed: 2004-06-28
Abstract: A sliding door mounting apparatus comprises a support member 1, adapted for attachment to a sliding door, and latch means. The support member 1 includes an aperture 2 (see figure 2) with a first portion dimensioned to allow a head 4 of a sliding door trolley connection member 200 to pass through. A second portion of the aperture 2 is dimensioned such that it can accommodate a neck portion 6 of the connection member 200, but does not allow the head 4 to pass through. This provides engagement between the support member 1 and connection member 200 when the neck 6 of the connection member 200 is accommodated in the second portion of the aperture 2. The latch means is adapted to retain the neck 6 in the second portion. A method of mounting a sliding door to a sliding door trolley connection member is also disclosed.
Patent NZ-534936-A (NZ)
Title: Restraint system for a floor conveying vehicle
Inventor: SAUERMANN HANS
IPC: B60R21/13
Filed: 2004-08-26
Abstract: A restraint system (1) for a vehicle, in particular a floor conveying vehicle, has a protective bar (8). The latter can be pivoted between an essentially vertically upwardly directed release position and an essentially horizontal restraint position assigned to a driver's seat. To further improve the restraint action, a seat belt (20) is fastened to the protective bar (8).
Patent NZ-535166-A (NZ)
Title: New medicinal compositions on the basis of anticholinergic agents and EGFR kinase inhibitors
Inventor: JUNG BIRGIT
IPC: A61K31/517
Filed: 2003-02-12
Abstract: Disclosed is a pharmaceutical composition, comprising one or more anticholinergics combined with one or more EGFR kinase inhibitors, wherein the anticholinergic is selected from a group consisting of tiotropium salts, oxitropium salts or ipratropium salts and wherein the EGFR kinase inhibitor is selected from a group of compounds described in the specification. Also disclosed is the use of said compositions in the treatment of inflammatory or obstructive diseases of the respiratory tract.